rationale

Sapu BioScience Highlights TGFB2-Guided Strategy to Enhance Taxane Therapies, Reinforcing the Rationale for Sapu-001

San Diego, CA, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Sapu BioScience today announced the publication of a new peer-reviewed study…

3 weeks ago

Lynozyfic (linvoseltamab) Monotherapy in Newly Diagnosed Multiple Myeloma (NDMM) Shows Impressive Responses, Supporting Rationale as a Potential Foundation in Frontline Treatment

All three dose groups (50 mg, 100 mg and 200 mg) showed impressive monotherapy efficacy, with VGPR+ (very good partial…

1 month ago